Skip to main content
PMC home page
The Journal of Clinical Endocrinology and Metabolism logoLink to The Journal of Clinical Endocrinology and Metabolism
. 2008 Mar 11;93(6):2097–2103. doi: 10.1210/jc.2007-2599

Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women

Barbara A Frempong 1, Madia Ricks 1, Sabyasachi Sen 1, Anne E Sumner 1
PMCID: PMC2435645  PMID: 18334585

Abstract

Context: The effect of oral contraceptive pill (OCP) use on cardiovascular risk in African-American women is unknown.

Objective: Our objective was to examine in African-American women the effect of OCP use on insulin resistance, glucose intolerance, and triglycerides (TGs).

Design: This was a cross-sectional study.

Setting: The study was conducted at the National Institutes of Health Clinical Research Center.

Participants: A total of 104 healthy nondiabetic African-American women [21 OCP users, 83 controls, age mean ± sd, 34.7 ± 7.6 yr, body mass index (BMI) 31 ± 8.4 kg/m2] was included in the study.

Interventions: Subjects had oral glucose tolerance tests, insulin-modified frequently sampled iv glucose tolerance tests, and fasting lipid profiles. Insulin resistance was determined by the insulin sensitivity index (SI).

Main Outcome Measures: Insulin resistance, glucose tolerance status, and TG levels were determined.

Results: Fasting glucose did not differ between OCP users and controls (P = 0.27). In contrast, compared with controls, 2-h glucose (135 ± 23 vs.120 ± 25 mg/dl; P = 0.01) and fasting TGs (73 ± 31 vs.57 ± 27 mg/dl; P = 0.02) were higher in OCP users. OCP users tended to be more insulin resistant than controls (SI: 2.51 ± 2.01 vs. 3.46 ± 2.09; P = 0.09). Multiple regression analysis revealed that BMI, age, and OCP use were significant determinants of 2-h glucose (adjusted R2 = 0.37; P < 0.001) and TG levels (adjusted R2 = 0.21; P < 0.001). As BMI was a determinant of both 2-h glucose and TGs, participants were divided into nonobese and obese groups, and the analyses repeated. Among the nonobese women, the OCP users were more insulin resistant (SI: 2.91 ± 1.58 vs. 4.35 ± 1.88; P = 0.03) and had a higher prevalence of glucose intolerance than controls (odds ratio 5.7; 95% confidence interval 1.4–24; P = 0.01).

Conclusion: In African-American women, OCP use is associated with an increase in markers of cardiovascular risk manifested by increased insulin resistance, glucose intolerance, and elevated TGs.

Non-obese African-American women taking low-dose oral contraceptive pills have lower glucose tolerance and higher fasting triglyceride levels.

In the United States, the oral contraceptive pill (OCP) is the leading form of contraception (1). Since its introduction in 1960, efforts have been directed to balance its risks and benefits. First-generation OCP preparations combined high-dose ethinyl estradiol (≥50 μg) and androgenic progestins, and were associated with several adverse effects, the most acute being strokes and thromboembolic events (2,3) In addition, OCP use was found to be associated with cardiovascular risk factors that promote myocardial infarctions in older populations. Therefore, it was assumed that OCP use would increase cardiovascular risk in women who use this form of contraception (3) In an attempt to minimize these adverse occurrences, oral contraceptives with lower doses of estrogen (≤50 μg ethinyl estradiol) and less androgenic progestins were developed (3,4,5). In the United States, most low-dose OCPs have estrogens in the range of 20–35 μg (2). Although low-dose oral contraceptives are associated with a better metabolic profile than higher doses, cardiovascular and embolic risks have not been eliminated (6,7).

Just as premenopausal women may elect to use the OCP, postmenopausal women may choose hormone replacement therapy (HRT). In postmenopausal women with an intact uterus, HRT usually consists of a combination of estrogen and progesterone. Many formulations of HRT are available. From HRT, important lessons have been learned about the effect of exogenous hormones on cardiovascular risk. Among the first studies to report that HRT decreased cardiovascular risk was the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (8). The PEPI investigators found that women on HRT had lower low-density lipoprotein (LDL), higher high-density lipoprotein (HDL), and lower fibrinogen. Subsequent to the PEPI trial, two large randomized placebo-controlled trials, the Heart and Estrogen/Progestin Replacement Study (HERS) (9) and the Women’s Health Initiative (WHI) (10), challenged the benefits and safety of HRT. In the HERS, postmenopausal women with established coronary disease were enrolled. In the first year of the HERS, increased coronary heart disease events, including myocardial infarction, sudden death, and congestive heart failure, were found (9).

The WHI studied healthy postmenopausal women without coronary artery disease. Results of the WHI provided insight into both the benefits and risks of HRT. In fact, the risks were determined to be so great that the WHI was terminated early because the women on HRT had an increased incidence of not only breast cancer but also of acute myocardial infarction, silent myocardial infarction, and deaths attributed to coronary heart disease (10). Yet, in the WHI younger women (50–59 yr) who were taking HRT for 7 yr had less coronary artery calcified plaque than control women (11). Therefore, the cardiovascular risk of exogenous estrogen and progesterone remains unresolved.

There is relatively little information available about the effect of exogenous hormones in African-American women. Postmenopausal African-American women are less likely than whites to use HRT and are often underrepresented in studies with HRT (12,13,14). Similarly, studies of OCP use have either not enrolled African-American women or enrolled too few African-American women to allow for the assessment of metabolic consequences of the OCP in African-Americans (14,15,16). In fact, it has been assumed that because African-American women have a high prevalence of glucose intolerance, the OCP would not pose a risk for African-American women (15).

In white women, OCP use has been documented to increase cardiovascular risk by promoting insulin resistance, glucose intolerance, and hypertriglyceridemia (15,16,17). However, compared with white women, African-American women are more insulin resistant, have a higher prevalence of glucose intolerance, and paradoxically lower triglyceride (TG) levels (18,19,20). Therefore, the metabolic effects of OCP observed in white women cannot be extrapolated to African-American women. Our goal was to study the effect of OCP use on insulin resistance, glucose tolerance status, and TG levels in African-American women.

Subjects and Methods

The participants were 104 healthy premenopausal African-American women [age 34.7 ± 7.6 yr (mean ± sd), range 22–50, and body mass index (BMI) 31 ± 8.4 kg/m2, range 18.9- 54.5]) enrolled in the Triglyceride and Cardiovascular Risk in African-Americans study at the National Institutes of Health, in Bethesda, MD (21,22). Of the women, 21 were OCP users, and 83 were not. OCP use was for contraceptive purposes only. The OCP formulations taken by the participants are provided Table 1. Women not using the OCP were considered controls. Of the control women, 63 participated in previous investigations (21,22). All participants were born in the United States and reported that both parents were African-American. Women 40 yr or older had gonadotropin levels to confirm premenopausal status. All subjects had normal hemograms, and liver, kidney, and thyroid function. Diabetics were excluded. Subjects took no other medications known to affect insulin resistance. Study participants were recruited by advertisements in local newsletters, flyers, and the National Institutes of Health web site. The study was approved by the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases. All subjects gave informed consent before participation.

Table 1.

List of oral contraceptives used by participants

Brand name No. Estrogen content (μg) Progestin content (mg)
Alesse (Wyeth Pharmaceuticals Inc., Philadelphia, PA) 3 20 Ethinyl estradiol 0.1 Levonorgestrel
Loestrin (Warner Chilcott, Rockaway, NJ) 1 20 Ethinyl estradiol 1 Norethindrone
Ortho Tri-Cyclen (Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ)a 5 35 Ethinyl estradiol 0.18/0.215/0.25 Norgestimate
Ortho-Novum 7/7/7 (Ortho-McNeil-Janssen Pharmaceuticals, Inc.)a 3 35 Ethinyl estradiol 0.5/0.75/1 Norethindrone
Lo/Ovral (Wyeth Laboratories, a Wyeth-Ayerst Co., Philadelphia, PA) 1 30 Ethinyl estradiol 0.3 Norgestrel
Ortho-Cept (Ortho-McNeil Pharmaceutical Inc., Raritan, NJ) 1 30 Ethinyl estradiol 0.15 Desogestrel
Ovcon −35 (Warner Chilcott) 2 35 Ethinyl estradiol 0.4 Norethindrone
Microgestin (Watson Pharmaceuticals Inc., Corona, CA) 1 20 Ethinyl estradiol 1 Norethindrone
Demulen 1/35 (Pfizer Inc., New York, NY) 1 35 Ethinyl estradiol 1 Ethynodiol
Yasmin (Bayer HealthCare Pharmaceuticals, Montville, NJ) 1 30 Ethinyl estradiol 3 Drospirenone
Mircette (Duramed Pharmaceuticals, Inc., Pomona, NY)b 2 20/10 Ethinyl estradiol 0.15/0 Desogestrel
Open in a new tab
a

Triphasic. 

b

Biphasic. 

The study consisted of three study visits conducted over 3 months. At the first visit, each subject had a history, physical examination, and screening blood work. Visits 2 and 3 were scheduled during the follicular phase of the menstrual cycle and occurred in the morning after a 12-h fast. At the second visit, all participants had a 75-g oral glucose tolerance test (Trutol 75; Custom Laboratories, Baltimore, MD) with glucose and insulin measured at 0 and 2 h. Fasting blood samples were taken for lipid profile and sex steroid measurements. Dual x-ray absorptiometry was performed to assess percent body fat. At 0800 h on the third visit, insulin modified-frequently sampled iv glucose tolerance tests were performed. Intravenous catheters were placed in each antecubital vein. At time zero, glucose (0.3 g/kg) was injected over 1 min. Insulin (4 mU/kg−1·min−1) was infused from 20–25 min. Blood samples for glucose and insulin were obtained at −10, −1, 0, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 min.

Assessment of social factors and family history

Alcohol use was defined as intake of more than one drink per week. Subjects were divided into three categories of tobacco use: 1) current smokers (women smoking at enrollment), 2) ex-smokers (women who had smoked in the past but not during the 12 months before enrollment), and (3) never smokers. Regular physical activity was defined as participating in recreational/fitness activities such as jogging, swimming, or cycling at least three times per week for 30–60 min each time. A positive family history of diabetes was defined as the presence of type 2 diabetes in a first-degree relative.

Analytical methods

Glucose was assayed using the glucose oxidase method (Glucostat; Yellow Springs Instrument Inc., Yellow Springs, OH). Insulin assays were performed using the double-antibody chemiluminescent sandwich assay (Diagnostic Products Corp., Los Angeles, CA). TGs were analyzed by enzymatic methods using an automated analyzer (Hitachi 917; Roche Molecular Biochemicals, Indianapolis, IN). HDL-cholesterol was measured by homogenous assay using synchron SX-20 analyzer (Beckman Coulter, Inc., Fullerton, CA). The glucose, insulin, TGs, and HDL-cholesterol were run in duplicate, and the coefficients of variation were 2, 4.9, 1.8, and 1.8%, respectively. Estradiol levels were obtained by competitive chemiluminescence immunoassay, and SHBG was measured with immunometric assay with chemiluminescence detection (Diagnostic Products). The interassay coefficient of variation for estradiol and SHBG levels were 8.6 and 5.4%, respectively.

Determination of insulin resistance

Insulin resistance was determined by the insulin sensitivity index (SI) using minimal model analyses and data from the insulin-modified frequently sampled iv glucose tolerance test (23) (Min Mod Millennium V6.02; MinMod. Inc., Los Angeles, CA).

Insulin secretion

Acute insulin response to glucose (AIRg) during the insulin-modified frequently sampled iv glucose tolerance test was calculated as the area under the insulin curve for insulin concentration above basal from 0–10 min. The disposition index (DI) was calculated to determine if pancreatic β-cell secretion was adequate to overcome the level of insulin resistance. The DI is the product of SI and AIRg (24).

Measurement of percent body fat

Percent body fat measurements were performed with a Hologic QDR 4500A dual energy x-ray absorptiometer in the array mode, using software version 5.71 (Hologic, Inc., Bedford, MA).

Statistical analysis

Data are presented as mean ± sd. Comparisons between OCP users and controls were performed using unpaired t tests. Parameters that were not normally distributed were transformed before analysis by log or square root as appropriate. χ2 tests were used for comparisons of categorical variables. The likelihood of having impaired glucose tolerance was determined in OCP users and controls by calculating the odds ratio. Multiple regression analyses were performed with either 2-h glucose or fasting TG as dependent variables, and BMI, age, and OCP use as the independent variables. A P value less than or equal to 0.05 was considered significant. The statistical analyses were performed using statistical data analysis software STATA version 10.0 (StataCorp LP, College Station, TX).

Results

The characteristics of the participants are listed in Table 2. Compared with controls, OCP users were younger (P = 0.05). OCP users had a trend toward lower BMI and lower percent body fat than controls, albeit the difference did not reach statistical significance. Family history of diabetes and the social factors that can influence glucose metabolism such as alcohol use, cigarette smoking, and physical activity did not differ between OCP users and controls (Table 2).

Table 2.

Characteristics of study population

Characteristics Controls (n = 83) OCP users (n = 21) P valuesa
Age (yr) 35.4 ± 7.6 31.8 ± 7.3 0.05
BMI (kg/m2) 31.5 ± 8.5 28.9 ± 8.2 0.22
Body fat (%) 36.4 ± 7.7 33.6 ± 8.6 0.11
Current smokers 11% 5% 0.40b
Alcohol intake of ≤ 1 drink per wk 80% 67% 0.21b
Regular physical activityc 25% 33% 0.46b
Family history of DM 52% 48% 0.73b
Prevalence of IGT 24% 43% 0.09b
Fasting glucose (mg/dl) 85 ± 8 83 ± 7 0.27
2-h glucose (mg/dl) 120 ± 25 135 ± 23 0.01
SI (liter/mU−1·min−1)d 3.46 ± 2.09 2.51 ± 2.01 0.09
AIRg (mU/liter−1·min)d 860 ± 585 613 ± 552 0.11
DId 2356 ± 1464 1373 ± 737 0.01
Total cholesterol (mg/dl) 170 ± 33 173 ± 37 0.76
TGs (mg/dl) 57 ± 27 73 ± 31 0.02
HDL-cholesterol (mg/dl) 52 ± 11 61 ± 14 0.01
LDL-cholesterol (mg/dl) 106 ± 30 97. ± 29 0.22
SHBG (nmol/liter) 48.2 ± 26.3 118.7 ± 67.9 0.01
Estradiol (pg/ml) 79.2 ± 62.9 59 ± 79.5 0.01
Open in a new tab

Data are presented as mean ± sd. DM, Diabetes mellitus; IGT, impaired glucose tolerance. 

a

Unless otherwise stated, comparisons were by the t test. 

b

Analyses by the χ2 test. 

c

Physical activity is defined as participating in recreational/fitness activity such as jogging, swimming, or cycling for at least three times per week for 30–60 min each time. 

d

Data in 78 subjects (63 controls, 15 OCP users). 

Fasting glucose was not different by OCP use (P = 0.27), but 2-h glucose obtained from the oral glucose tolerance tests was higher in OCP users than controls (135 ± 23 vs. 120 ± 25 mg/dl; P = 0.01). Similarly, the DI (the product of SI and AIRg) was significantly lower in OCP users compared with controls (P = 0.01) (Table 2).

Both TGs and HDL-cholesterol were higher in OCP users than controls (P ≤ 0.02), but total cholesterol and LDL-cholesterol did not differ (Table 2).

SHBG levels were higher in OCP users than controls (P = 0.01). Estradiol levels were lower in OCP users than controls (P = 0.01).

Multiple regression analysis revealed that BMI, age, and OCP use were significant determinants of 2-h glucose with adjusted R2 = 0.37 (P < 0.001) (Table 3). Similarly, BMI, age, and OCP use were significant determinants of TG levels with adjusted R2 = 0.21 (P < 0.05). As BMI was a significant determinant of both 2-h glucose and TG, we examined how BMI categories modified the effect of OCP use on cardiovascular risk factors. Women were divided into two categories [nonobese (BMI < 30) and obese (BMI ≥ 30)], and the analyses were repeated.

Table 3.

Regression analyses showing the independent contributions of BMI, OCP use, and age to 2-h glucose and TG

BMI OCP use Age
Dependent variable = 2-h glucose
 Adjusted R2 = 0.37
  β-Coefficient 1.144 22.908 1.219
  se 0.246 5.084 0.275
  P value <0.001 <0.001 <0.001
Dependent variable = TG
 Adjusted R2 = 0.21
  β-Coefficient 0.656 22.778 1.069
  se 0.326 6.662 0.353
  P value 0.047 0.001 0.003
Open in a new tab

Metabolic and hormonal profile in nonobese women

Compared with controls, OCP users were younger (P = 0.05) (Table 4). OCP users were more insulin resistant than controls, as evidenced by their higher fasting insulin levels (P = 0.05), higher 2-h glucose (P = 0.01), and lower SI (P = 0.03). Consequently, the prevalence of glucose intolerance was higher in OCP users than in controls (36 vs. 9%; P = 0.01). Similarly, OCP users had a higher likelihood of having glucose intolerance than controls (odds ratio = 5.7; 95% confidence interval 1.4–24; P = 0.01).

Table 4.

Characteristics of nonobese subjects

Characteristics Controls (n = 45) OCP users (n = 14) P valuesa
Age (yr) 34.6 ± 8.1 29.7 ± 6.8 0.05
BMI (kg/m2) 25.1 ± 2.8 24.3 ± 3.7 0.37
Body fat (%) 31.4 ± 5.6 28.8 ± 5.6 0.13
Current smokers 7% 7% 0.95b
Alcohol intake of ≤ 1 drink per wk 80% 57% 0.09b
Regular physical activityc 33% 43% 0.52b
Family history of DM 49% 50% 0.94b
Prevalence of IGT 9% 36% 0.01b
Fasting insulin (μU/ml) 6.1 ± 2.4 7.6 ± 2.2 0.05
Fasting glucose (mg/dl) 82 ± 6 80.3 ± 6.8 0.40
2-h glucose (mg/dl) 112 ± 22 130 ± 22.5 0.01
SI (liter/mU−1·min−1)d 4.35 ± 1.88 2.91 ± 1.58 0.03
AIRg (mU/liter−1·min)d 667. ± 347 658.4 ± 387.6 0.95
DId 2657.8 ± 1529.5 1616 ± 718 0.04
Total cholesterol (mg/dl) 162 ± 30 177 ± 35 0.12
TGs (mg/dl) 49 ± 19 75 ± 34 <0.01
HDL-cholesterol (mg/dl) 54 ± 11 65 ± 13 <0.01
LDL-cholesterol (mg/dl) 98 ± 27 96 ± 29 0.86
SHBG (nmol/liter) 52.5 ± 25.7 138.8 ± 66.8 <0.01
Estradiol (pg/ml) 84.2 ± 63.6 48.6.4 ± 87.1 <0.01
Open in a new tab

Data are presented as mean ± sd. DM, Diabetes mellitus; IGT, impaired glucose tolerance. 

a

Unless otherwise stated, comparisons were by the t test. 

b

Analyses by the χ2 test. 

c

Physical activity is defined as participating in recreational/fitness activity such as jogging, swimming, or cycling for at least three times per week for 30–60 min each time. 

d

Data in 42 subjects (32 controls, 10 OCP users). 

In addition, compared with controls, OCP users had higher TGs and HDL-cholesterol (P < 0.01), but total cholesterol and LDL-cholesterol were not statistically different (Table 4). OCP users had higher SHBG levels (P = <0.01) and lower estradiol levels (P < 0.01).

Metabolic and hormonal profile in obese women

In contrast to the nonobese women, obese OCP users compared with obese controls had no difference in age, fasting insulin, 2-h glucose, SI, TG, or HDL-cholesterol. Consequently, the prevalence of glucose intolerance in obese OCP users and controls was similar (57 vs. 42%; P = 0.46).

Discussion

We are the first to examine the association between cardiovascular risk factors and OCP use specifically in African-American women. Our investigation revealed that compared with controls, African-American women taking low-dose OCP have worse glucose tolerance and higher fasting TG levels. Most importantly, the differences between OCP users and controls in cardiovascular risk factors were greatest in the subgroup of nonobese women. Previous studies in white women have suggested that among women taking the OCP, those at highest risk for developing glucose intolerance were obese (25,26). Our observation of significantly worse glucose tolerance and TG elevations in nonobese African-American users of the OCP suggests that for nonobese African-American women, OCP may pose additional health risks.

Although elevations in both fasting and 2-h glucose levels are associated with increased cardiovascular risk, 2-h glucose may be a better predictor of cardiovascular disease risk than fasting blood glucose (27,28). In our study, whereas fasting glucose was unaffected by OCP use, 2-h glucose levels were higher in users compared with controls. Consistent with our findings, Sheu et al. (29) showed in Chinese women that OCP use did not affect fasting glucose but was associated with higher 2-h glucose. Interestingly, this pattern has also been observed with HRT in postmenopausal women (30).

Elevation in 2-h glucose is an indication of glucose intolerance. Glucose intolerance results from both insulin resistance and decreased β-cell function. OCP use promotes glucose intolerance by affecting both pathways (15). The exact mechanism by which OCP use leads to insulin resistance has not been fully elucidated. However, a proposed mechanism is reduced insulin receptor binding (31). This phenomenon has been demonstrated by comparing insulin receptor binding and affinity in monocytes isolated from OCP users and controls. In the normal menstrual cycle, insulin receptor binding and affinity are lower in the luteal than the follicular phase, suggesting that insulin resistance is worse in the luteal than follicular phase (32). De Pirro et al. (31) demonstrated that OCP users have lower insulin binding and affinity similar to that observed in the luteal phase of the menstrual cycle in normal women.

In addition to promoting insulin resistance, OCP use leads to impaired β-cell function (15). The relationship between insulin secretion and insulin resistance is best represented by the DI. The DI is a measure of whether insulin secretion by the β-cell is sufficient to compensate for the level of insulin resistance. Watanabe et al. (15) have shown in white women that the DI is lower in OCP users than controls, suggesting that OCP use in white women is associated with compromised β-cell function. Our study of African-American women also found impaired β-cell function with OCP use because the DI was lower in the OCP users than controls (Table 2).

Besides altering glucose metabolism, OCP use leads to an increase in both TGs and HDL-cholesterol. With exposure to estrogen, hepatic synthesis and secretion of TG-rich particles increase (33,34). Many studies have demonstrated that increased TG levels are an independent risk for cardiovascular disease (35,36,37). Hokanson and Austin (36) reported that especially in women, elevations in TGs are associated with an increased risk of cardiovascular disease, even after adjusting for HDL-cholesterol levels. Therefore, by causing an increase in TG levels, OCP use may be worsening cardiovascular risk.

HDL-cholesterol levels increase with OCP use because estrogen inhibits hepatic lipase activity, the enzyme responsible for clearing HDL-cholesterol from the circulation (33,38). In contrast, hepatic lipase activity is promoted by the androgenic effect of progesterone, leading to an increased clearance of HDL-cholesterol and lower circulating HDL-cholesterol levels (33,38,39). However, with OCP use the overall net effect favors estrogen’s inhibition of hepatic lipase, resulting in an increase in HDL-cholesterol levels. Because OCP use leads to increased HDL-cholesterol, it would be anticipated that cardiovascular risk might be lower with OCP use. However, definitive evidence that pharmacologically increased HDL-cholesterol improves cardiovascular outcomes is not available (9,40).

Different preparations of the OCP do not equally affect cardiovascular risk. Because the participants in our study were on 11 different preparations, we cannot address this issue or distinguish the relative effect of the estrogen and progestin components. The negative effect of the progestin component may be directly related to the type and dose of progesterone. Identifying the risk associated with different progestin preparations has been a major emphasis of European investigators (7,39).

The major weaknesses of our study are the sample size, cross-sectional design, and the number of different OCP preparations used. However, despite our sample size, our findings of significantly higher 2-h glucose, worse insulin resistance, higher TGs and HDL, and a lower DI in OCP users are consistent with reports in larger cohorts (15,16,17,29). Furthermore, SHBG and estradiol, both of which are known to be affected by OCP use, were significantly different in OCP users than controls. We also carefully examined family history and the social factors that could potentially confound our results such as smoking and alcohol, and they did not differ between OCP users and controls. It is our belief that our results justify the design of larger prospective studies of African-American women taking the OCP.

In evaluating sample size, we must also consider the risk of OCP use in relation to body size and age. After the study population was divided into nonobese and obese groups, the difference in risk factors was significant only in the nonobese women. Thus, nonobese women who should not have had these risk factors now may do so because of their OCP use. For obese women the situation is different. As obesity itself increases the baseline risk for insulin resistance and dyslipidemia, a larger sample size would be needed to detect a difference, if one exists, between obese OCP users and controls. In addition, the OCP users were younger than the controls. By virtue of being younger, it would be expected that the OCP users would have lower TGs and less glucose intolerance. The fact that OCP users had higher TGs and more glucose intolerance again magnifies the importance of the differences between users and controls.

In African-American women, low-dose OCP use was associated with an increased risk of insulin resistance, glucose intolerance, and elevated TGs. As each of these factors may promote adverse cardiovascular outcomes (27,36), it is possible that the OCP is presenting a risk to African-American women. Assessing the risks and benefits of OCP use is complex and requires careful consideration in African-American women.

Acknowledgments

We thank Drs. Pamela Stratton and Lynnette Nieman for their thoughtful and critical review of the manuscript. We also thank the participants for their time and effort.

Footnotes

This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Intramural Research Program.

Disclosure Information: The authors have nothing to declare.

First Published Online March 11, 2008

Abbreviations: AIRg, Acute insulin response to glucose; BMI, body mass index; DI, disposition index; HDL, high-density lipoprotein; HERS, Heart and Estrogen/Progestin Replacement Study; HRT, hormone replacement therapy; LDL, low-density lipoprotein; OCP, oral contraceptive pill; PEPI, Postmenopausal Estrogen/Progestin Interventions; SI, insulin sensitivity index; TG, triglyceride; WHI, Women’s Health Initiative.

References

  1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ 2004 Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data 1–36 [PubMed] [Google Scholar]
  2. David PS, Boatwright EA, Tozer BS 2006 Hormonal contraception update. Mayo Clin Proc 81:949–954 [DOI] [PubMed] [Google Scholar]
  3. Godsland IF, Crook D, Wynn V 1992 Clinical and metabolic considerations of long-term oral contraceptive use. Am J Obstet Gynecol 166(6 Pt 2):1955–1963 [DOI] [PubMed] [Google Scholar]
  4. Piper JM, Kennedy DL 1987 Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 16:215–221 [DOI] [PubMed] [Google Scholar]
  5. Baillargeon JP, McClish DK, Essah PA, Nestler JE 2005 Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863–3870 [DOI] [PubMed] [Google Scholar]
  6. Chasan-Taber L, Stampfer MJ 1998 Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 128:467–477 [DOI] [PubMed] [Google Scholar]
  7. Dinger JC, Heinemann LA, Kuhl-Habich D 2007 The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75:344–354 [DOI] [PubMed] [Google Scholar]
  8. 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA [Erratum (1995) 274:1676] 273:199–208 [PubMed] [Google Scholar]
  9. Hulley S, Grady D, Bush T 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613 [DOI] [PubMed] [Google Scholar]
  10. Manson JE, Hsia J, Johnson KC, Roussow JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women’s Health Initiative Investigators 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534 [DOI] [PubMed] [Google Scholar]
  11. Manson JE, Allison MA, Rossouw JE 2007 Estrogen therapy and coronary-artery calcification. N Engl J Med 356:2591–2602 [DOI] [PubMed] [Google Scholar]
  12. Nicholson WK, Brown AF, Gathe J, Grumbach K, Washington AE, Perez-Stable EJ 1999 Hormone replacement therapy for African-American women: missed opportunities for effective intervention. Menopause 6:147–155 [PubMed] [Google Scholar]
  13. Weng HH, McBride CM, Bosworth HB, Grambow SC, Siegler IC, Bastian LA 2001 Racial differences in physician recommendation of hormone replacement therapy. Prev Med 33:668–673 [DOI] [PubMed] [Google Scholar]
  14. Russell-Briefel R, Ezzati TM, Perlman JA, Murphy RS 1987 Impaired glucose tolerance in women using oral contraceptives: United States, 1976–1980. J Chronic Dis 40:3–11 [DOI] [PubMed] [Google Scholar]
  15. Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN 1994 Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 79:1277–1283 [DOI] [PubMed] [Google Scholar]
  16. Simon D, Senan C, Garnier P 1990 Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study. Am J Obstet Gynecol 163(1 Pt 2):382–387 [DOI] [PubMed] [Google Scholar]
  17. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V 1992 Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64–70 [DOI] [PubMed] [Google Scholar]
  18. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW 2006 Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268 [DOI] [PubMed] [Google Scholar]
  19. Sumner AE, Cowie CC 2008 Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 196:696–703 [DOI] [PubMed] [Google Scholar]
  20. Palaniappan LP, Carnethon MR, Fortmann SP 2002 Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin. Diabetes Care 25:1351–1357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sumner AE, Farmer NM, Cochran CS 2001 Obese premenopausal African-American women with normal and impaired glucose tolerance have a similar degree of insulin resistance but differ in beta-cell function. Diabetes Care 24:1978–1983 [DOI] [PubMed] [Google Scholar]
  22. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC 2005 Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 165:1395–1400 [DOI] [PubMed] [Google Scholar]
  23. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN 2003 MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003–1015 [DOI] [PubMed] [Google Scholar]
  24. Kahn SE, Prigeon RL, McCulloch DK 1993 Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672 [DOI] [PubMed] [Google Scholar]
  25. Duffy TJ, Ray R 1984 Oral contraceptive use: prospective follow-up of women with suspected glucose intolerance. Contraception 30:197–208 [DOI] [PubMed] [Google Scholar]
  26. Harvengt C 1992 Effect of oral contraceptive use on the incidence of impaired glucose tolerance and diabetes mellitus. Diabete Metab 18:71–77 [PubMed] [Google Scholar]
  27. DECODE Study Group, the European Diabetes Epidemiology Group 2001 Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405 [DOI] [PubMed] [Google Scholar]
  28. Coutinho M, Gerstein HC, Wang Y, Yusuf S 1999 The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240 [DOI] [PubMed] [Google Scholar]
  29. Sheu WH, Hsu CH, Chen YS, Jeng CY, Fuh MM 1994 Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptives. Clin Endocrinol (Oxf) 40:249–255 [DOI] [PubMed] [Google Scholar]
  30. van Genugten RE, Utzschneider KM, Tong J, Gerchman F, Zraika S, Udayasankar J, Boyko EJ, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group 2006 Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. Diabetes 55:3529–3535 [DOI] [PubMed] [Google Scholar]
  31. De Pirro R, Forte F, Bertoli A, Greco AV, Lauro R 1981 Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab 52:29–33 [DOI] [PubMed] [Google Scholar]
  32. Bertoli A, De Pirro R, Fusco A, Greco AV, Magnatta R, Lauro R 1980 Differences in insulin receptors between men and menstruating women and influence of sex hormones on insulin binding during the menstrual cycle. J Clin Endocrinol Metab 50:246–250 [DOI] [PubMed] [Google Scholar]
  33. Krauss RM, Burkman Jr RT 1992 The metabolic impact of oral contraceptives. Am J Obstet Gynecol 167(4 Pt 2):1177–1184 [DOI] [PubMed] [Google Scholar]
  34. Sondheimer SJ 1991 Update on the metabolic effects of steroidal contraceptives. Endocrinol Metab Clin North Am 20:911–923 [PubMed] [Google Scholar]
  35. Sharrett AR, Ballantyne CM, Coady SA 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108–1113 [DOI] [PubMed] [Google Scholar]
  36. Hokanson JE, Austin MA 1996 Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219 [PubMed] [Google Scholar]
  37. Sarwar N, Danesh J, Eiriksdottir G 2007 Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450–458 [DOI] [PubMed] [Google Scholar]
  38. Petersen KR 2002 Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 49:43–60 [PubMed] [Google Scholar]
  39. Godsland IF, Crook D, Wynn V 1991 Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med 36(Suppl):226–237 [PubMed] [Google Scholar]
  40. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators 2007 Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med [Erratum (2007) 357:835] 356:1304–1316 [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Clinical Endocrinology and Metabolism are provided here courtesy of The Endocrine Society

RESOURCES